Thompson M S, Read J L, Hutchings H C, Paterson M, Harris E D
Institute for Health Research, Harvard School of Public Health, Cambridge, MA.
J Rheumatol. 1988 Jan;15(1):35-42.
In a 6-month randomized trial at 14 sites, the cost effectiveness of auranofin (AF) treatment for patients with rheumatoid arthritis was gauged in comparison with placebo. Measures of global health and of impacts on daily life suggest that the benefits of disease modification outweigh adverse effects after 4 and 6 months of treatment (p less than 0.01), with negligible differences between placebo and treated patients after 1 and 2 months. Additional medical costs directly associated with AF treatment amounted to $778/patient annually. Observed differences in less direct medical costs, help received, and earnings were not statistically significant.
在一项为期6个月、涉及14个地点的随机试验中，对金诺芬（AF）治疗类风湿性关节炎患者的成本效益与安慰剂进行了比较。整体健康状况及对日常生活影响的测量结果表明，治疗4个月和6个月后，疾病改善带来的益处超过了不良反应（p<0.01），而在治疗1个月和2个月后，安慰剂组和治疗组患者之间的差异可忽略不计。与AF治疗直接相关的额外医疗费用为每年每位患者778美元。在不太直接的医疗费用、获得的帮助及收入方面观察到的差异无统计学意义。
